HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mototsugu Muramaki Selected Research

Prostatectomy (Retropubic Prostatectomy)

12/2014Assessment of postoperative quality of life: comparative study between laparoscopic and minimum incision endoscopic radical prostatectomies.
1/2014Comparison of postoperative infection between robotic-assisted laparoscopic prostatectomy and open radical prostatectomy.
11/2013Prognostic significance of primary Gleason pattern in Japanese men with Gleason score 7 prostate cancer treated with radical prostatectomy.
7/2013Efficacy of using three-tesla magnetic resonance imaging diagnosis of capsule invasion for decision-making about neurovascular bundle preservation in robotic-assisted radical prostatectomy.
6/2010Characterization of the anatomical extension pattern of localized prostate cancer arising in the peripheral zone.
3/2010Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
2/2010Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension.
3/2009Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
1/2009Adverse prognostic impact of capsular incision at radical prostatectomy for Japanese men with clinically localized prostate cancer.
9/2006Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mototsugu Muramaki Research Topics

Disease

28Neoplasms (Cancer)
11/2020 - 11/2003
22Prostatic Neoplasms (Prostate Cancer)
05/2016 - 02/2005
14Urinary Bladder Neoplasms (Bladder Cancer)
08/2010 - 11/2003
8Neoplasm Metastasis (Metastasis)
11/2020 - 10/2004
8Lymphatic Metastasis
12/2011 - 10/2004
7Renal Cell Carcinoma (Grawitz Tumor)
11/2020 - 10/2005
7Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
12/2014 - 09/2003
5Margins of Excision
11/2013 - 01/2006
4Nonseminomatous germ cell tumor
10/2010 - 09/2004
4Disease Progression
01/2006 - 05/2005
2Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
05/2022 - 01/2013
2Carcinoma (Carcinomatosis)
10/2020 - 12/2011
2Choriocarcinoma
12/2014 - 10/2010
2Extranodal Extension
07/2013 - 06/2010
2Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
03/2013 - 02/2010
2Hyperplasia
09/2008 - 08/2003
2Testicular Neoplasms (Testicular Cancer)
07/2006 - 10/2004
2Transitional Cell Carcinoma
01/2006 - 05/2005
1Adrenocortical Carcinoma
05/2022
1Rheumatoid Arthritis
05/2022
1Lymphoproliferative Disorders (Lymphoproliferative Disorder)
05/2022
1Ureteral Obstruction
09/2020
1Hypertension (High Blood Pressure)
01/2016
1Postoperative Hemorrhage
06/2015
1Infections
01/2014
1Surgical Blood Loss
11/2013
1Chronic Renal Insufficiency
01/2013
1Non-Muscle Invasive Bladder Neoplasms
03/2012
1Cerebral Hemorrhage
04/2011
1Brain Neoplasms (Brain Tumor)
04/2011
1Thyroiditis
09/2010
1Hypothyroidism
09/2010

Drug/Important Bio-Agent (IBA)

8Cisplatin (Platino)FDA LinkGeneric
12/2014 - 09/2003
8ClusterinIBA
02/2010 - 02/2005
4Prostate-Specific Antigen (Semenogelase)IBA
06/2010 - 01/2006
4AndrogensIBA
09/2008 - 02/2005
3Methotrexate (Mexate)FDA LinkGeneric
05/2022 - 04/2008
3Paclitaxel (Taxol)FDA LinkGeneric
12/2014 - 01/2007
3Antisense OligonucleotidesIBA
06/2011 - 09/2008
3Therapeutic UsesIBA
03/2006 - 09/2005
3Proteins (Proteins, Gene)FDA Link
10/2005 - 11/2003
3OligodeoxyribonucleotidesIBA
05/2005 - 02/2005
3O-(Chloroacetylcarbamoyl)fumagillol (TNP 470)IBA
03/2005 - 11/2003
2Angiogenesis InhibitorsIBA
11/2020 - 11/2003
2OligonucleotidesIBA
05/2016 - 01/2007
2C-Reactive ProteinIBA
01/2014 - 05/2009
2Docetaxel (Taxotere)FDA Link
12/2012 - 03/2005
2Cadherins (E-Cadherin)IBA
03/2012 - 12/2011
2Etoposide (VP 16)FDA LinkGeneric
10/2010 - 12/2007
2Biomarkers (Surrogate Marker)IBA
02/2010 - 01/2006
2GemcitabineFDA Link
02/2009 - 10/2004
2Bleomycin (Blenoxane)FDA LinkGeneric
04/2008 - 12/2007
2Tumor Biomarkers (Tumor Markers)IBA
12/2007 - 09/2005
2HSP27 Heat-Shock ProteinsIBA
01/2007 - 03/2006
2Insulin-Like PeptidesIBA
05/2005 - 02/2005
1NivolumabIBA
11/2020
1CreatinineIBA
01/2015
1IfosfamideFDA LinkGeneric
12/2014
1ElementsIBA
12/2014
1Sunitinib (Sutent)FDA Link
04/2011
1Dactinomycin (Actinomycin)FDA LinkGeneric
10/2010
1Sorafenib (BAY 43-9006)FDA Link
09/2010
1Thyroid HormonesIBA
09/2010
1Thyrotropin (Thyroid-Stimulating Hormone)FDA Link
09/2010
1Thyroxine (Levothyroxine)FDA LinkGeneric
09/2010
1Triiodothyronine (Liothyronine)FDA LinkGeneric
09/2010
1Pemetrexed (MTA)FDA Link
06/2010
1Interferon-alpha (Interferon Alfa)IBA
05/2009
1Interleukin-2 (IL2)IBA
05/2009
1Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
03/2009
1Plasminogen Activator Inhibitor 2IBA
03/2009
1Plasminogen Activator Inhibitor 1IBA
03/2009
1Urokinase Plasminogen Activator ReceptorsIBA
03/2009
1Plasminogen Activators (Plasminogen Activator)IBA
03/2009
1OGX-011IBA
02/2009

Therapy/Procedure

19Therapeutics
11/2020 - 11/2003
16Prostatectomy (Retropubic Prostatectomy)
12/2014 - 09/2005
9Drug Therapy (Chemotherapy)
12/2012 - 07/2004
8Nephrectomy
06/2015 - 05/2009
5Cystectomy
08/2010 - 05/2005
4Adrenalectomy
05/2022 - 08/2003
4Operative Time
06/2016 - 11/2013
4Neoadjuvant Therapy
11/2013 - 11/2005
3Warm Ischemia
06/2016 - 01/2015
3Castration
05/2016 - 06/2011
3Combination Drug Therapy (Combination Chemotherapy)
04/2008 - 09/2003
2Stents
09/2020 - 01/2006
2Induction Chemotherapy
12/2014 - 09/2004
2Nephroureterectomy
12/2011 - 01/2008
2Radiotherapy
04/2011 - 05/2005
2Lymph Node Excision (Lymph Node Dissection)
02/2010 - 09/2004
2Immunotherapy
05/2009 - 01/2004
2Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)
07/2006 - 07/2004
1Metastasectomy
11/2020
1Transurethral Resection of Bladder
10/2020
1Duration of Therapy
01/2016
1Solid-State Lasers
03/2013
1Morcellation
03/2013
1Aftercare (After-Treatment)
04/2011
1MEA regimen
10/2010